Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: Results of a two-year strict observational study

Journal of Bone and Mineral Metabolism

Volumn 27, Issue 2, 2009, Pages 168-174

  Majima, Takafumi ^a   Shimatsu, Akira ^a   Komatsu, Yasato ^b   Satoh, Noriko ^a   Fukao, Atsushi ^d   Ninomiya, Kiyoshi ^c   Matsumura, Tadashi ^c   Nakao, Kazuwa ^b  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c RAKUWAKAI OTOWA HOSPITAL   (Japan)

^d AINO UNIVERSITY   (Japan)

Author keywords

Alfacalcidol; Bone mineral density; Male; Osteoporosis; Risedronate

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIUM; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EPIGASTRIC DISCOMFORT; FATIGUE; FEMUR NECK; FRAGILITY FRACTURE; GENDER; HUMAN; JAPANESE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; OBSERVATIONAL STUDY; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; RADIUS;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BACK PAIN; BODY HEIGHT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIUM; ETIDRONIC ACID; FRACTURES, BONE; HUMANS; HYDROXYCHOLECALCIFEROLS; JAPAN; MALE; MIDDLE AGED; OSTEOPOROSIS; PHOSPHATES;

EID: 60849131228     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-008-0024-8     Document Type: Article

References (19)

1. H Orimo T Hashimoto K Sakata N Yoshimura T Suzuki T Hosoi 2000 Trends in the incidence of hip fracture in Japan, 1987-1997: the third nationwide survey J Bone Miner Metab 18 126 131
2. S Fujiwara F Kasagi N Masunari K Naito G Suzuki M Fukunaga 2003 Fracture prediction from bone mineral density in Japanese men and women J Bone Miner Res 18 1547 1553
3. J Iwamoto T Takeda Y Sato 2005 Prevention and treatment of corticosteroid-induced osteoporosis Yonsei Med J 46 456 463
4. T Majima Y Komatsu K Doi C Takagi M Shigemoto A Fukao T Morimoto J Corners K Nakao 2006 Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease J Bone Miner Metab 24 105 113
5. JD Ringe H Faber P Farahmand A Dorst 2006 Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study Rheumatol Int 26 427 431
6. M Shiraki M Fukunaga K Kushida H Kishimoto Y Taketani H Minaguchi T Inoue R Morita H Morii K Yamamoto Y Ohashi H Orimo 2003 A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the risedronate late phase II research group) Osteoporos Int 14 225 234
7. M Shiraki M Fukuchi T Kiriyama S Okamoto T Ueno H Sakamoto T Nagai 2004 Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis J Bone Miner Metab 22 352 359
8. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis Calcif Tissue Int 54 370 376
9. 3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study Endocr J 43 211 220
10. M Shiraki K Kushida M Fukunaga H Kishimoto M Taga T Nakamura K Kaneda H Minaguchi T Inoue H Morii A Tomita K Yamamoto Y Nagata M Nakashima H Orimo 1999 A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate phase III osteoporosis treatment research group Osteoporos Int 10 183 192
11. T Tanizawa K Imura Y Ishii S Nishida Y Takano T Mashiba N Endo HE Takahashi 1999 Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study Osteoporos Int 9 163 170
12. F Richy O Ethgen O Bruyere JY Reginster 2004 Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate Osteoporos Int 15 301 310
13. T Fujita H Orimo T Inoue K Kaneda M Sakurai R Morita K Yamamoto Y Sugioka A Inoue K Takaoka I Yamamoto Y Hoshino H Kawaguchi 2007 Clinical effect of bisphosphonate and vitamin D on osteoporosis: reappraisal of a multicenter double-blind clinical trial comparing etidronate and alfacalcidol J Bone Miner Metab 25 130 137
14. H Orimo Y Hayashi M Fukunaga T Sone S Fujiwara M Shiraki K Kushida S Miyamoto S Soen J Nishimura Y Oh-Hashi T Hosoi I Gorai H Tanaka T Igai H Kishimoto Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone, Mineral Research 2001 Diagnostic criteria for primary osteoporosis: year 2000 revision J Bone Miner Metab 19 331 337
15. T Fujita Y Fujii SF Okada A Miyauchi Y Takagi 2001 Analgesic effect of etidronate on degenerative joint disease J Bone Miner Metab 19 251 256
16. J Takada K Iba K Imoto T Yamashita 2007 Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate J Bone Miner Metab 25 142 146
17. T Mashiba S Mori DB Burr S Komatsubara Y Cao T Manabe H Norimatsu 2005 The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib J Bone Miner Metab 23 S36 S42
18. T Nakamura World Health Organization 2007 Absolute risk for fracture and WHO guideline. Fracture risk assessments recommended by World Health Organization and Japanese guidelines for prevention and treatment of osteoporosis 2006 Clin Calcium 17 1022 1028
19. H Kishimoto M Fukunaga K Kushida M Shiraki A Itabashi H Nawata T Nakamura H Ohta K Takaoka Y Ohashi Risedronate Phase III Research Group 2006 Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen J Bone Miner Metab 24 405 413